PMH18: USE OF NONBARBITURATE SEDATIVE/ HYPNOTIC AGENTS IN AN AMBULATORY POPULATION  by Hornquist, M et al.
Abstracts 83
began therapy on a conventional medication, while 1,035
(24%) started on an atypical medication. Only 67 pa-
tients initiated treatment using 2 antipsychotics simul-
taneously. Time-to-event analysis of treatment discontin-
uation (mono-atypical vs. mono-conventional vs. multi-
therapy) found that the probabilities of discontinuing
therapy differed by year of prescription. In more current
prescription years, patients initiating atypical therapy
were more likely to remain on therapy than those starting
on conventional agents. CONCLUSION: Atypical agents
appear to provide improved performance in treatment
continuation.
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RESEARCH OBJECTIVE: Novel antipsychotic medica-
tions have several advantages over traditional agents in
the treatment of schizophrenia. Little is known about fac-
tors that affect prescribing of novel agents. This study ex-
amines variation in novel antipsychotic prescribing at 13
VA Medical Centers from six Veterans Integrated Service
Networks (VISNs). STUDY DESIGN: Using automated
data from 13 VA Medical Centers at six VISNs, we iden-
tified 740 patients with an outpatient prescription for an-
tipsychotic medication following their last discharge with
a diagnosis of schizophrenia in 1997. Most patients
(711) were male. Approximately 46% were African
American, 46% were white, and 7% were Hispanic.
Mean age was 48.5 (range 22–89). POPULATION
STUDIED: Schizophrenic patients. PRINCIPAL FIND-
INGS: Novel antipsychotic medications were prescribed
for 46.2% of the subjects, with significant variation
among the facilities (2  24.9, df  12, P  0.015,
range 26.8–58.9%) and less significant variation among
the VISNs (2  9.85, df  5, P  0.08, range 39.5–
54.4%). About 6% of the patients (46) were given depot
antipsychotic medications. Only 1 person received both
depot and novel antipsychotic medications. Although the
study population consisted of approximately equal num-
bers of white and African American subjects, 72% (33)
of the subjects prescribed depot antipsychotics were Afri-
can Americans. White patients were more likely than
non-whites to receive novel antipsychotic medications
(OR  1.836, P  0.0002) controlling for marital status,
gender, age, and facility. CONCLUSIONS: Less than
half of patients with schizophrenia are receiving novel
antipsychotic medications in this sample. In addition,
there is significant variation among facilities as well as by
ethnicity. IMPLICATIONS FOR DELIVERY AND
PRACTICE: The variation among facilities as well as by
ethnicity suggests that prescribing practices for these
agents could be improved. Further research is needed to
determine the factors that influence these practices.
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Treatment guidelines for bipolar disorder recommend
constant drug therapy with a mood stabilizing medica-
tion and prompt drug treatment for manic and depressive
episodes. The use patterns and duration of mood stabiliz-
ing therapy in real world practice are unclear. OBJEC-
TIVES: This study documents the use patterns and dura-
tion of therapy for mood stabilizing medications used to
treat bipolar disorder patients and explores the factors
that affect compliance with drug therapy. METHODS:
Medi-Cal data covering 1993–99 were used to identify
4,813 adult bipolar patients with at least one prescrip-
tion for a mood stabilizer filled during the first 12
months of their treatment episode. Compliance was de-
fined as a medication possession ratio for mood stabiliz-
ers in excess of 0.9 during the first 12 months after the
initiation of drug therapy. Logistic regression analysis
was conducted using SAS. RESULTS: 1,765 patients
(36.7%) initiated therapy on a mood stabilizer; 612
(12.7%) and 965 (20%) used an antidepressants or an-
tipsychotic as initial therapy, respectively; 1,471 (30.6%)
used multiple medications as initial therapy. The compli-
ance rate was 12.4%. A diagnosis of bipolar-manic disor-
der significantly increased the likelihood of compliance
(odds ratio  1.74), as did a diagnosis of schizophrenia
(1.33), and initiation of therapy on an atypical antipsy-
chotic (1.47). Delays in the initiation of mood stabilizer
therapy and the selection of valproic acid as the initial
mood stabilizer significantly reduced the likelihood of
compliance (odds ratio  0.642, P  0.002 for valporic
acid). CONCLUSIONS: Current drug treatment patterns
for bipolar disorder are far from ideal. Delays in mood
stabilizer use and drug selection are important determi-
nants of mood stabilizer use patterns that are consistent
with treatment guidelines.
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Scarce data exists to characterize the nature of recent sed-
ative/hypnotic use in ambulatory patients. Clinical litera-
ture suggests that use of these agents has adverse conse-
quences related to physical and mental functioning that
may be of particular concern to older individuals. Ad-
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ministrative data provides an opportunity to examine
this use in the general population. OBJECTIVES: The
study purpose was to investigate how sedative/hypnotic
drugs are used in an ambulatory population. METH-
ODS: A retrospective analysis of prescription claims from
an integrated database. Persons with at least one pre-
scription for a nonbarbiturate sedative/hypnotic in a 36-
month sampling frame (1/1/95–12/31/97) were included.
Sedative/hypnotic agents included: estazolam, ethchlor-
vynol, flurazepam, glutethimide, quazepam, temazepam,
triazolam, and zolpidem. RESULTS: 55,086 persons had
at least one claim for the drugs of interest. 58% were fe-
male, the average age was 62 years  14.5 years, with a
range of 3–104 years. 58% of those identified were 60
years of age. Women were only slightly older than men
(62.1 years compared to 61.8 years). The most com-
monly used agent during the study timeframe was zolpi-
dem (a short-acting agent) with 58% of identified sub-
jects having at least one claim. This was followed by
temazepam (an intermediate acting agent) used by 36%
of persons identified. 53% of persons using zolpidem and
36% of persons using temazepam were 60 years of age.
27% of persons identified had claims evidence suggestive
of single, one time acquisition of a sedative/hypnotic
agent during a 12-month period of time. CONCLUSION:
The majority of persons in this ambulatory population
used short or intermediate acting sedative/hypnotics, for
extended use. A large number of patients 60 years of
age rely on benzodiazepine-based agents (temazepam)
that can produce daytime sedation which may decrease
daytime functioning.
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OBJECTIVE: This study documented the relationship be-
tween antipsychotic drug use patterns and direct health
care costs for community-dwelling patients with schizo-
phrenia in four state Medicaid programs. METHODS: A
one-year treatment period was defined for each patient
(N  18,090). Logistic regression models were used to
investigate the predictors of not having used any medica-
tion, delaying therapy, changes in therapy, and complet-
ing one year of continuous therapy. Regression analyses
were used to estimate the impact of these patterns of an-
tipsychotic drug use on direct health care costs. RESULTS:
The average annual total direct cost for community-
dwelling patients with schizophrenia was $13,650 (N 
18,090). Approximately 24% of patients did not use any
antipsychotic drug for at least one year and consumed
significantly fewer services ($3,200). Delaying antipsy-
chotic therapy (18%) was associated with an increase in
total cost of care of $3,936 (P  0.0001). Patients who
switched or augmented their initial therapy (41%) were
also found to experience higher total cost of care
($4,019, P  0.0001). Continuous antipsychotic therapy
(18%) was associated with significant shifts in the type of
care consumed ($1,337 in hospital costs; $652 in nurs-
ing home costs; $1,237 in ambulatory services and $939
in other services), leaving total cost unchanged. CONCLU-
SIONS: A significant proportion of patients with schizo-
phrenia treated with traditional antipsychotic medica-
tions did not display drug utilization patterns consistent
with successful drug therapy. Suboptimal drug use pat-
terns were associated with increased direct healthcare costs.
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OBJECTIVE: This study examined medical resource con-
sumption by patients with chronic and breakthrough
pain (BTP) who were using transdermally-delivered fent-
anyl for the management of chronic pain. Patients were
participants in a broader survey designed to collect clini-
cal and economic information regarding their pain.
METHODS: Surveys were administered to cancer and
non-cancer patients with chronic and BTP to assess med-
ical resources consumed in the past 30 days. Patients
were identified from investigator practices and asked to
participate in an interview. Data were collected for physi-
cian contacts, Emergency Department (ED) visits, hospi-
talizations, prescription use, patient work loss, and care-
giver time and work loss. RESULTS: 102 patients were
enrolled at the time of this analysis; 95 (93%) completed
the survey. Forty (42%) were men and 55 (58%) were
women. 42% reported calling and 44% visited their phy-
sician’s office, averaging 1.05 telephone calls and 0.68
visits specifically because of BTP. Patients averaged 2.55
prescriptions for pain control during the period. Twelve
patients (13%) reported 16 ED visits, and 11 patients
(12%) reported 13 hospitalizations. Only 20 of the 95
patients (21%) were working in a paid job. Of these,
70% (14/20) reported lost work, an average of 36.9
hours during the prior 30 days, due to pain. Nearly 83%
of patients reported having someone help with their per-
sonal and/or medical care. Caregivers spent an average of
77 hours helping patients. Twenty-four patients (25%)
reported an average of 24 hours of caregiver work loss as
a result. CONCLUSIONS: The magnitude of medical re-
source consumption due to pain is notable, and lost work
